Loading clinical trials...

COMPLETED

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

NCT04855617•NYU Langone Health

View on ClinicalTrials.gov

Summary

This study is designed to determine whether symptom burden differs by time to infusion.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 18-80
•Diagnosis of multiple sclerosis (revised 2017 criteria)
•EDSS 0-7
•Plans to initiate treatment with ocrelizumab within 6 months or has been on an approved regimen of ocrelizumab for \>12 months as part of their clinical care
•Individual must be able to provide consent, read/write/comprehend English Language

Exclusion Criteria

•Clinical relapse within 3 months of first on-study infusion
•Cognitive impairment limiting the ability to consent or fill out the electronic survey
•Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding
•Untreated psychiatric illness (such as major depressive disorder, Bipolar disorder, psychotic disorder, schizophrenia)
•Active substance abuse disorder
•Significant medical comorbidities (such as history of severe traumatic brain injury, stroke, systemic cancer or chronic infection)
•Chemotherapy use within 6 months of first study infusion
•Prior treatment with alemtuzumab within 12 months of first study infusion
•Prior treatment with a B-cell depleting therapy other than ocrelizumab within 12 months of first on-study infusion

Locations (2)

Elliot Lewis Center for Multiple Sclerosis Care

Wellesley, Massachusetts, United States

NYU Langone Health Multiple Sclerosis Comprehensive Care Center (NYULH MSCCC)

New York, New York, United States

Key Dates

Start Date

October 26, 2020

Primary Completion Date

October 1, 2022

Completion Date

October 1, 2022

Last Updated

June 15, 2023

Enrollment

122

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

Ocrelizumab

DRUG

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study